LLY Jan 2024 400.000 call
| Previous close | 157.39 |
| Open | 165.20 |
| Bid | 156.70 |
| Ask | 160.05 |
| Strike | 400.00 |
| Expiry date | 2024-01-19 |
| Day's range | 156.60 - 165.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 489 |
Motley Fool3 Magnificent Growth Stocks to Buy Right Now
Three Fool.com contributors believe they've identified truly magnificent growth stocks to buy right now. Here's why they chose AstraZeneca (NASDAQ: AZN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (AstraZeneca): What makes AstraZeneca a magnificent long-term investment is how broad the business is and the potential it has to generate long-term gains.
BloombergObesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
(Bloomberg) -- The global market for novel weight-loss drugs like Novo Nordisk A/S’s Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications.Most Read from BloombergChinese Gold Buying Is Driving a Paradigm Shift in BullionWells Fargo Preps for Wealth Battle After $1 Billion TurnaroundUS to Keep a Distance From India-Canada Dispute, Signum’s Myers SaysBond Market Faces Quandary After Fed Signals It’s Almost DoneRaw Meat-Eating Li
Motley FoolAre Wall Street Analysts Wrong About Eli Lilly Stock?
Based on analysts' projections, you might think the pharmaceutical giant isn't worth investing in right now.
